A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of LY2940094 in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs BTRX 246040 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- 14 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 May 2011 Planned End Date changed from 1 Jun 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.